RxDoctor Payments Data

Susan Hanson

Adult Health · Honesdale, PANPI 1437230497

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 413 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,446in general payments, 2019–2025

Across 413 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • GSK$765
  • Bayer$749
  • Daiichi Sankyo Inc.$528
  • Otsuka America Pharmaceutical, Inc.$438
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$7,446100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,446 in reported general payments places this provider in the 90th percentile of 899 adult health providers in Pennsylvania.

See all adult health providers in Pennsylvania

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban242$175,724
JanuviaSitagliptin Phosphate70$70,106
OzempicSemaglutide39$46,482
RybelsusSemaglutide39$36,543
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$35,426
Breo ElliptaFluticasone/Vilanterol49$30,181
XareltoRivaroxaban30$24,354
FarxigaDapagliflozin Propanediol29$20,969
TrulicityDulaglutide21$19,027
JardianceEmpagliflozin16$17,604
RexultiBrexpiprazole11$16,528
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$9,704
TradjentaLinagliptin17$8,763
MyrbetriqMirabegron13$8,448
DuleraMometasone/Formoterol19$8,255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$341$175,724242 claims
Novo NordiskOzempic, Rybelsus$1,254$83,02578 claims
MerckJanuvia, Dulera$37$78,36189 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$765$72,170117 claims
Boehringer IngelheimJardiance, Tradjenta$16$26,36733 claims
Johnson & JohnsonXarelto$87$24,35430 claims
AstraZenecaFarxiga$246$20,96929 claims
Lilly USA, LLCTrulicity$352$19,02721 claims
Otsuka America Pharmaceutical, Inc.Rexulti$438$16,52811 claims
Astellas Pharma US IncMyrbetriq$81$8,44813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 899 adult health providers in Pennsylvania.

Other adult health in Honesdale

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →